← Back to Press PAGE

Cure51 wants to sequence the DNA of survivors

Cure51

Publication Date:

Mar 14, 2025

"Nicolas Wolikow, co-founder and president of Cure 51, was Laure Closier's guest on French Tech on Friday, March 14. He explained his company's work with cancer survivors on Good Morning Business. "

Watch the video

NEWS

THEY SPREAD THE WORD

Go to Press page

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025

Join us to eradicate Cancer.

ROSALIND

Cure51 wants to sequence the DNA of survivors

Publication Date:

Mar 14, 2025

Table of Contents

THEY SPREAD THE WORD

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025